Revolution Medicines, Inc. - Common Stock (RVMD)
31.27
-1.61 (-4.88%)
NASDAQ · Last Trade: Apr 6th, 9:46 PM EDT

Via Benzinga · July 16, 2024

Via Benzinga · July 9, 2024

Via Benzinga · July 9, 2024

Via Benzinga · November 7, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via Benzinga · November 6, 2023

Via Benzinga · December 4, 2024

Via Benzinga · December 2, 2024

Via Benzinga · December 2, 2024

Via Benzinga · December 2, 2024

Via Benzinga · July 16, 2024

Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder
Via InvestorPlace · June 8, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via InvestorPlace · June 4, 2024

RVMD stock results show that Revolution Medicines beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 8, 2024

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via Benzinga · April 12, 2024

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
Via Benzinga · April 10, 2024

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
Via Benzinga · April 10, 2024

U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
Via Benzinga · April 10, 2024

Via Benzinga · March 8, 2024

A technical analysis of REVOLUTION MEDICINES INC.
Via Chartmill · February 1, 2024

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via InvestorPlace · December 15, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via Benzinga · February 26, 2024

Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
Via InvestorPlace · November 16, 2023

Raymond James initiated coverage on Revolution Medicines Inc (NASDAQ: RVMD), noting that the October readout of RMC-6236 was compelling compared to historical SoC.
Via Benzinga · November 16, 2023